{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:46:30Z","timestamp":1759009590644},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-1020-y","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T11:11:34Z","timestamp":1439896294000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Masanori","family":"Atsukawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Furihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Chuganji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"1020_CR1","unstructured":"World Health Organization. Fact sheet No164. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ ."},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362:1292\u2013303.","journal-title":"N Engl J Med"},{"key":"1020_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195\u2013206.","journal-title":"N Engl J Med"},{"key":"1020_CR5","doi-asserted-by":"crossref","unstructured":"Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et al. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:219\u201327.","DOI":"10.1016\/j.jhep.2014.04.004"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742\u201348.","journal-title":"Hepatology"},{"key":"1020_CR7","doi-asserted-by":"crossref","unstructured":"Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97\u00a0% and 100\u00a0% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359\u201365. e351.","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"1020_CR8","doi-asserted-by":"crossref","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. ION-2 Investigators, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u201393.","DOI":"10.1056\/NEJMoa1316366"},{"key":"1020_CR9","doi-asserted-by":"crossref","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. ION-1 Investigators, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","DOI":"10.1056\/NEJMoa1402454"},{"key":"1020_CR10","doi-asserted-by":"crossref","unstructured":"Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50\u00a0years and older: a meta-analysis. Lancet. 2007;370:657\u201366.","DOI":"10.1016\/S0140-6736(07)61342-7"},{"key":"1020_CR11","doi-asserted-by":"crossref","unstructured":"Ginde AA, Scragg R, Schwartz RS, Camargo CA, Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57:1595\u2013603.","DOI":"10.1111\/j.1532-5415.2009.02359.x"},{"key":"1020_CR12","doi-asserted-by":"crossref","unstructured":"Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009;30:113\u201325.","DOI":"10.1111\/j.1365-2036.2009.04022.x"},{"key":"1020_CR13","doi-asserted-by":"crossref","unstructured":"Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case\u2013control study. Carcinogenesis. 2008;29:93\u20139.","DOI":"10.1093\/carcin\/bgm240"},{"key":"1020_CR14","doi-asserted-by":"crossref","unstructured":"Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000;11:847\u201352.","DOI":"10.1023\/A:1008923802001"},{"key":"1020_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/carcin\/bgp055","volume":"30","author":"J Ahn","year":"2009","unstructured":"Ahn J, Albanes D, Berndt SI, Prostate, Lung, Colorectal and Ovarian Trial Project Team, et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009;30:769\u201376.","journal-title":"Carcinogenesis"},{"key":"1020_CR16","doi-asserted-by":"crossref","unstructured":"Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820\u20135.","DOI":"10.1093\/ajcn\/79.5.820"},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1017\/S0007114509992017","volume":"103","author":"PR Hurst von","year":"2010","unstructured":"von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr. 2010;103:549\u201355.","journal-title":"Br J Nutr"},{"key":"1020_CR18","doi-asserted-by":"crossref","unstructured":"Kozawa K, Imawari M, Shimazu H, Kobori O, Osuga T, Morioka Y. Vitamin D status after total gastrectomy. Dig Dis Sci. 1984;29:411\u20136.","DOI":"10.1007\/BF01296215"},{"key":"1020_CR19","doi-asserted-by":"crossref","unstructured":"Imawari M, Kozawa K, Akanuma Y, Koizumi S, Itakura H, Kosaka K. Serum 25-hydroxyvitamin D and vitamin D-binding protein levels and mineral metabolism after partial and total gastrectomy. Gastroenterology. 1980;79:255\u20138.","DOI":"10.1016\/0016-5085(80)90137-7"},{"key":"1020_CR20","doi-asserted-by":"crossref","unstructured":"Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010;51:1158\u201367.","DOI":"10.1002\/hep.23489"},{"key":"1020_CR21","unstructured":"Imawari M, Akanuma Y, Itakura H, Muto Y, Kosaka K, Goodman DS. The effects of diseases of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. J Lab Clin Med. 1979;93:171\u201380."},{"key":"1020_CR22","doi-asserted-by":"crossref","unstructured":"Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C\/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011;53:1118\u201326.","DOI":"10.1002\/hep.24201"},{"key":"1020_CR23","doi-asserted-by":"crossref","unstructured":"Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, et al. Serum 25-hydroxyvitamin D levels affect treatment outcome in pegylated interferon\/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. Hepatol Res. 2014;44:1277\u201385.","DOI":"10.1111\/hepr.12298"},{"key":"1020_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.dld.2014.05.004","volume":"46","author":"M Atsukawa","year":"2014","unstructured":"Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, et al. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir\/peg-interferon\/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis. 2014;46:738\u201343.","journal-title":"Dig Liver Dis"},{"key":"1020_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/bjd.12349","volume":"169","author":"Z Lagunova","year":"2013","unstructured":"Lagunova Z, Porojnicu AC, Aksnes L, et al. Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial. Br J Dermatol. 2013;169:434\u201340.","journal-title":"Br J Dermatol"},{"key":"1020_CR26","doi-asserted-by":"crossref","unstructured":"Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab. 2007;92:2130\u20135.","DOI":"10.1210\/jc.2006-2250"},{"key":"1020_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266\u201381.","journal-title":"N Engl J Med"},{"key":"1020_CR28","doi-asserted-by":"crossref","unstructured":"Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325\u201335.","DOI":"10.1002\/hep.24013"},{"key":"1020_CR29","doi-asserted-by":"crossref","unstructured":"Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol. 2000;33:812\u20137.","DOI":"10.1016\/S0168-8278(00)80314-1"},{"key":"1020_CR30","unstructured":"Yenice N, Gumrah M, Mehtap O, Kozan A, Turkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol. 2006;17:260\u20136."},{"key":"1020_CR31","doi-asserted-by":"crossref","unstructured":"Nessvi S, Johansson L, Jopson J, Stewart A, Reeder A, McKenzie R, et al. Association of 25-hydroxyvitamin D3 levels in adult New Zealanders with ethnicity, skin color and self-reported skin sensitivity to sun exposure. Photochem Photobiol. 2011;87:1173\u20138.","DOI":"10.1111\/j.1751-1097.2011.00956.x"},{"key":"1020_CR32","doi-asserted-by":"crossref","unstructured":"Morel PA, Manolagas SC, Provvedini DM, Wegmann DR, Chiller JM. Interferon-gamma-induced IA expression in WEHI-3 cells is enhanced by the presence of 1,25-dihydroxyvitamin D3. J Immunol. 1986;136:2181\u20136.","DOI":"10.4049\/jimmunol.136.6.2181"},{"key":"1020_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0006-291X(84)90719-8","volume":"121","author":"DM Provvedini","year":"1984","unstructured":"Provvedini DM, Deftos LJ, Manolagas SC. 1,25-Dihydroxyvitamin D3 receptors in a subset of mitotically active lymphocytes from rat thymus. Biochem Biophys Res Commun. 1984;121:277\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"1020_CR34","unstructured":"Kankova M, Luini W, Pedrazzoni M, Riganti F, Sironi M, Bottazzi B, et al. Impairment of cytokine production in mice fed a vitamin D3-deficient diet. Immunology. 1991;73:466\u201371."},{"key":"1020_CR35","doi-asserted-by":"crossref","unstructured":"von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol. 2010;11:344\u20139.","DOI":"10.1038\/ni.1851"},{"key":"1020_CR36","doi-asserted-by":"crossref","unstructured":"Manuel Quesada J, Solana R, Serrano I, Barrio V, Martinez ME, Santamaria M, et al. Immunologic effects of vitamin D. N Engl J Med. 1989;321:833\u20134.","DOI":"10.1056\/NEJM198909213211215"},{"key":"1020_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.diabres.2006.10.007","volume":"77","author":"A Giulietti","year":"2007","unstructured":"Giulietti A, van Etten E, Overbergh L, et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract. 2007;77:47\u201357.","journal-title":"Diabetes Res Clin Pract"},{"key":"1020_CR38","doi-asserted-by":"crossref","unstructured":"Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol. 2007;103:558\u201362.","DOI":"10.1016\/j.jsbmb.2006.12.093"},{"key":"1020_CR39","doi-asserted-by":"crossref","unstructured":"Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, et al. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod. 2006;75:816\u201322.","DOI":"10.1095\/biolreprod.106.054056"},{"key":"1020_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/ije\/dym247","volume":"37","author":"KE Nnoaham","year":"2008","unstructured":"Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008;37:113\u20139.","journal-title":"Int J Epidemiol"},{"key":"1020_CR41","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/hep.24575","volume":"54","author":"M Gal-Tanamy","year":"2011","unstructured":"Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology. 2011;54:1570\u20139.","journal-title":"Hepatology"},{"key":"1020_CR42","doi-asserted-by":"crossref","unstructured":"Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology. 2012;56:1231\u20139.","DOI":"10.1002\/hep.25763"},{"key":"1020_CR43","doi-asserted-by":"crossref","unstructured":"Kondo Y, Kato T, Kimura O, Iwata T, Ninomiya M, Kakazu E, et al. 1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN\/RBV therapy in chronic hepatitis C patients-case controlled trial. PLoS One. 2013;8:e63672.","DOI":"10.1371\/journal.pone.0063672"},{"key":"1020_CR44","doi-asserted-by":"crossref","unstructured":"Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54:887\u201393.","DOI":"10.1016\/j.jhep.2010.08.036"},{"key":"1020_CR45","doi-asserted-by":"crossref","unstructured":"Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int. 2011;24:43\u201350.","DOI":"10.1111\/j.1432-2277.2010.01141.x"},{"key":"1020_CR46","doi-asserted-by":"crossref","unstructured":"Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, et al. Efficacy of Alfacalcidol on PEG-IFN\/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13:e14872.","DOI":"10.5812\/hepatmon.14872"},{"key":"1020_CR47","doi-asserted-by":"crossref","unstructured":"Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012;56:1641\u201350.","DOI":"10.1002\/hep.25848"},{"key":"1020_CR48","doi-asserted-by":"crossref","unstructured":"Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Tsuji K, et al. Effect of vitamin D supplementation on pegylated interferon\/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014;21:348\u201356.","DOI":"10.1111\/jvh.12146"},{"key":"1020_CR49","doi-asserted-by":"crossref","unstructured":"Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728\u201337.","DOI":"10.1136\/gut.2010.234666"},{"key":"1020_CR50","doi-asserted-by":"crossref","unstructured":"Bandeira F, Griz L, Dreyer P, Eufrazino C, Bandeira C, Freese E. Vitamin D deficiency: A global perspective. Arq Bras Endocrinol Metabol. 2006;50:640\u20136.","DOI":"10.1590\/S0004-27302006000400009"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1020-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-1020-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1020-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T06:56:50Z","timestamp":1691909810000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-1020-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-1020-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]},"article-number":"344"}}